Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
12.58
+0.18 (+1.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
February 01, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday.
Via
Benzinga
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
January 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday
January 23, 2024
U.S. stocks traded mixed, with the Dow Jones index falling around 70 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Expert Outlook: Arcutis Biotherapeutics Through The Eyes Of 7 Analysts
January 03, 2024
Via
Benzinga
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
January 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 19, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 16, 2024
Via
Benzinga
What 8 Analyst Ratings Have To Say About Arcutis Biotherapeutics
November 06, 2023
Via
Benzinga
Earnings Outlook For Arcutis Biotherapeutics
November 02, 2023
Via
Benzinga
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
January 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Flexsteel Industries Posts Strong Preliminary Results, Joins Wipro, Sify Technologies And Other Big Stocks Moving Higher In Friday's Pre-Market Session
January 12, 2024
U.S. stock futures were mixed this morning, with the Dow futures gaining around 50 points on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 28, 2023
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 19, 2023
Via
Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 18, 2023
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic...
Via
Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is One of Monday Morning’s Most Active Stocks
December 18, 2023
Via
Investor Brand Network
Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
December 18, 2023
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 18, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 18, 2023
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning!
Via
InvestorPlace
FDA Approves Arcutis Biotherapeutics' Lead Drug For Scaly Skin Disorder
December 18, 2023
The FDA approved Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) Zoryve (roflumilast) topical foam, 0.3% for seborrheic dermatitis in individuals
Via
Benzinga
Exposures
Product Safety
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
December 15, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 15, 2023
Via
Benzinga
FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6
November 29, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
3 Biotech Stocks With Key Catalysts Coming in December
November 15, 2023
Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.
Via
InvestorPlace
DraftKings To Rally Over 48%? Here Are 10 Top Analyst Forecasts For Monday
November 06, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 03, 2023
Via
Benzinga
Top 5 Health Care Stocks That Are Preparing To Pump In November
November 03, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
November 03, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
MSP Recovery And 3 Other Stocks Under $3 Insiders Are Buying
October 27, 2023
The Dow Jones closed lower by over 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For November 3, 2023
November 03, 2023
Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.